Tonix Pharmaceuticals Selects EVERSANA To Support Launch Strategy And Commercialization Planning Of Tonmya For The Management Of Fibromyalgia
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals has partnered with EVERSANA to support the launch and commercial planning of Tonmya, a non-opioid analgesic for fibromyalgia management, in the U.S. Tonmya has shown significant results in Phase 3 trials and plans to submit a New Drug Application to the FDA in the second half of 2024. EVERSANA will help Tonix navigate the fibromyalgia market and develop a go-to-market strategy.
March 06, 2024 | 1:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals is advancing the commercialization of Tonmya for fibromyalgia with EVERSANA's support, aiming for FDA submission in 2H 2024 after positive Phase 3 results.
The partnership with EVERSANA to support the launch and commercial planning of Tonmya, coupled with the positive results from Phase 3 trials, positions Tonix Pharmaceuticals favorably for future growth. The successful commercialization and potential FDA approval of Tonmya could significantly impact the company's stock price positively in the short term, given the unmet need in fibromyalgia treatment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100